Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Highlights

A collection of news and information related to Pradaxa (drug) published by this site and its partners.

Sort By: Relevancy | Date | Type
Displaying items 1-7 of 7
» View wdbj7.com items only
    May 15, 2013 |Story| Hartford Courant

  1. Pharmaceutical Firm's Growth Bucks State Trend

    At Boehringer Ingelheim Pharmaceuticals, the second-largest drug company in Connecticut, the local workforce increased by more than 40 percent over the last 10 years, at the same time its employee numbers worldwide grew by 35 percent.
    The Hartford Courant
    At Boehringer Ingelheim Pharmaceuticals, the second-largest drug company in Connecticut, the local workforce increased by more than 40 percent over the last 10 years, at the same time its employee numbers worldwide grew by 35 percent. A company that...

    Tags: Danbury, Medical Research, Science, New Haven (New Haven, Connecticut), Companies and Corporations

    2. Apr 29, 2013 |Story| Los Angeles Times

  2. FDA approves a drug to reverse anticoagulation

    Ever since the drug warfarin was discovered to be a highly effective anti-clotting agent as well as a good rat poison in the early 1950s, it has been the frontline weapon in preventing stroke among those with atrial fibrillation. But its growing use has always raised the specter of dangerously hard-to-stanch bleeding if someone taking it is wounded or bleeds internally from a fall or a car accident.
    Ever since the drug warfarin was discovered to be a highly effective anti-clotting agent as well as a good rat poison in the early 1950s, it has been the frontline weapon in preventing stroke among those with atrial fibrillation. But its growing use has...

    Tags: Xarelto (drug), Cardiac Arrhythmia, Health Organizations, Dietary Supplements, Vitamin K

    3. Apr 24, 2013 |Story| Reuters

  3. Boehringer anti-clotting pill gains blockbuster status

    Reuters
    INGELHEIM, Germany, April 24 (Reuters) - Boehringer Ingelheim said its anti-blood-clotting drug Pradaxa reached blockbuster status in 2012, helping the world's largest unlisted drugmaker to an 11.5 percent rise in sales for last year. Sales of the pill,...

    Tags: Drugs and Medicines, Xarelto (drug), Germany, Diabetes, Johnson & Johnson Inc.

    4. Nov 12, 2012 |Story| Reuters

  4. Cost becomes bigger question in treating heart disease

    LOS ANGELES (Reuters) - The cost of treating heart disease has become a key factor in decisions by U.S. cardiologists grappling with the nation's No. 1 killer.
    Reuters
    LOS ANGELES (Reuters) - The cost of treating heart disease has become a key factor in decisions by U.S. cardiologists grappling with the nation's No. 1 killer. Record prices for drugs and devices, reduced reimbursement by insurance plans and the...

    Tags: Cardiologists, Chest Pains, Hospitals and Clinics, Stroke, Diabetes

    5. Jan 10, 2012 |Story| Los Angeles Times
  5. |Story
    6. Nov 14, 2011 |Story| Reuters

  6. Doctors reserve judgment on new blood clot drugs

    ORLANDO, Florida (Reuters) - Cardiologists are not ready to jump to any conclusions about a closely-watched group of new blood thinners and said serious questions about their safety still need to be addressed.
    Reuters
    ORLANDO, Florida (Reuters) - Cardiologists are not ready to jump to any conclusions about a closely-watched group of new blood thinners and said serious questions about their safety still need to be addressed. Three new medicines that offer potential...

    Tags: Cardiologists, Skin Cancer, Culture, American Heart Association, Arts and Culture

    7. Aug 28, 2011 |Story| Reuters

  7. New Bristol, Pfizer clot drug saves lives in study

    PARIS (Reuters) - An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market.
    Reuters
    PARIS (Reuters) - An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market. Although Eliquis will...

    Tags: Brain, Medical Research, Cardiologists, Thomson Corporation, Duke University

Original site for Pradaxa (drug) topic gallery.